The prices of many commonly used drugs in India are set to fall anything from 0.2% to 70.3% from October, the country's Chemicals and Fertilizers Minister, Ram Vialas Paswan, told reporters. The cost of anti-AIDS drugs are also likely to fall with two state-owned companies preparing them, he said.
Meanwhile, four private Indian companies - Ranbaxy Laboratories, Torrent Pharmaceuticals, Unichem Laboratories and Alembic - have already submitted a list of 216 formulation packs to the government on which they will effect a 2% to 70% cut in retail prices by slashing trade margins from October 2, industry sources said.
A committee, headed by India's Chemicals and Petrochemicals Secretary, was set up to work out the modalities of price control. A close watch would be kept on drug prices and a notification issued, if needed, later. Drug banks would be set up at the district level from January 26 next year to provide free medicines to below poverty line (BPL) families.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze